Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice

Journal of Investigative Dermatology

Volumn 114, Issue 4, 2000, Pages 725-730

  Schlagbauer Wadl, Hermine ^a   Klosner, Gabriele ^a   Heere Ress, Elisabeth ^a   Waltering, Stefan ^b   Moll, Ingrid ^c   Wolff, Klaus ^a   Pehamberger, Hubert ^a   Jansen, Burkhard ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Department of Dermatology ^*  (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apoptosis; Tumor therapy; Xenotransplantation model

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; OBLIMERSEN; OLIGONUCLEOTIDE; PROTEIN BCL 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER THERAPY; CASE REPORT; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MERKEL CELL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; TUMOR REGRESSION; XENOTRANSPLANTATION;

EID: 0033993970     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00937.x     Document Type: Article

References (34)

1. Askari FK, McDonnell WM: Molecular medicine - antisense oligonucleotide therapy. NEJM 334:316-318, 1996
2. Ballas ZK, Rasmussen W, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157:1840-1845, 1996
3. Banerjee D: Technology evaluation: G3139. Curr Opin Mol Therapeutics 1:404-408, 1999
4. Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530, 1983
5. Campos L, Sabido O, Rouault J-P, Guyotat D: Effects of bcl-2 antisense oligodeoxynucleotides on in vitro cell proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595-600, 1994
6. Cotter FE, Johnson P, Hall P, Pocock C, Al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049-3055, 1994
7. Haag ML, Glass F, Fenske N: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21:669-683, 1995
8. Heike Y, Takahashi M, Ohira T, et al: In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice. Cancer Chemother Pharmacol 35:200-204, 1995
9. Hitchcock CL, Bland KI, Laney RG: Neuroendocrine (Merkel cell) carcinoma of the skin: its natural history, diagnosis, and treatment. Ann Surg 207:201-207, 1988
10. Hockenbery DM: Bcl-2 in cancer, development and apoptosis. J Cell Sci 18:51-55, 1994
11. Jansen B, Schlagbauer-Wadl H, Eichler H-G, Wolff K, van Elsas A, Schrier PI, Pehamberger H: Activated N-Ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 57:362-365, 1997
12. Jansen B, Schlagbauer-Wadl H, Brown BD, et al: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 4:232-234, 1998
13. Jansen B, Heere-Ress E, Schlagbauer-Wadl H, et al: Farnesylthiosalicylic acid (FTS) inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med in press, 1999
14. Kennedy MM, Blessing K, King G, Kerr KM: Expression of bcl-2 and p53 in Merkel cell carcinoma. Am J Dermatopathol 18:273-277, 1996
15. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA: Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucl Acids Res 24:737-745, 1996
16. Krasagakis K, Almond-Roesler B, Zouboulis CC, Tebbe B, Wartenberg E, Wolff K-D, Orfanos CE: Merkel cell carcinoma: report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivity. J Am Acad Dermatol 36:727-732, 1997
17. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3:614-620, 1997
18. Moll I, Bohnert E, Herbst C, Förster W, Moll R, Franke WW: Establishment and characterization of two Merkel cell tumor cultures. J Invest Dermatol 102:346-353, 1994
19. Moll I, Gillardon F, Waltering S, Schmelz M, Moll R: Differences of bcl-2 protein expression between Merkel cells and Merkel cell carcinomas. J Cutan Pathol 23:109-117, 1996
20. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett F, Crooke ST: Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Design 12:421-432, 1997
21. Neckers L, Whitesell L, Rosolen A, Geselowitz DA: Antisense inhibition of oncogene expression. Crit Rev Oncogenes 3:175-231, 1992
22. O'Connor WJ, Brodland DG: Merkel cell carcinoma. Dermatol Surg 22:262-267, 1996
23. Paine-Murrieta GD, Taylor CW, Curtis RA, et al: Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 40:209-214, 1997
24. Pectasides D, Moutzourides G, Dimitriadis M, Varthalitis J, Athanassiou A: Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide. Am J Clin Oncol 18:418-420, 1995
25. Plettenberg A, Pammer J, Tschachler E: Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol 5:102-107, 1996
26. Ratner D, Nelson BR, Brown MD, Johnson TM: Merkel cell carcinoma. J Am Acad Dermatol 29:143-159, 1993
27. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
28. Sharma D, Flora G, Grunberg SM: Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol 14:166-169, 1991
29. Stein CA: Does antisense exist? Nature Med 1:1119-1121, 1995
30. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214-5218, 1986
31. Wagner RW: The state of the art in antisense research. Nature Med 1:1116-1118, 1995
32. Webb A, Cunningham D, Cotter F, et al: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141, 1997
33. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ: Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89:2994-2998, 1997
34. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK: Merkel cell carcinoma. Prognosis and management. Arch Surg 126:1514-1519, 1991